Molecular mechanism of action for reversible P2Y12 antagonists

被引:9
|
作者
Liu, Haibo [2 ]
Ge, Hu [1 ]
Peng, Yong [2 ]
Xiao, Peigen [2 ]
Xu, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Plant Dev, Beijing 100194, Peoples R China
关键词
P2Y(12) receptor; ADP; Antagonists; Platelets aggregation; SWISS-MODEL REPOSITORY; CLOPIDOGREL PLUS ASPIRIN; ANTIPLATELET THERAPY; RECEPTOR ANTAGONIST; COST-EFFECTIVENESS; P2; RECEPTORS; FREE-ENERGY; PROTEIN; PREVENTION; P2Y12;
D O I
10.1016/j.bpc.2011.03.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, reversible antagonists of the P2Y(12) receptor have been reported. However, the mechanisms of binding have not been elucidated. To this end, a number of homology models were built by means of three programs from four templates. A consensus model was derived from those initial models. The final model was created by refining the consensus model with molecular dynamics simulations. The agonist and antagonists of P2Y(12) have been docked in the final model. For the agonist, the Arg256, Lys280, and Phe252 are "hot" residues. For the antagonists, the Lys280 and Phe252 are "hot" residues that have hydrogen bonding contacts and pi-pi interactions, respectively. These results can explain the observations of mutation experiments and can guide the design of new inhibitors. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 50 条
  • [41] Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists
    Tang, Jie
    Li, Mu-Peng
    Zhou, Hong-Hao
    Chen, Xiao-Ping
    CURRENT VASCULAR PHARMACOLOGY, 2015, 13 (05) : 566 - 577
  • [42] P2Y12 receptor antagonists:: a rapidly expanding group of antiplatelet agents
    Cattaneo, M
    EUROPEAN HEART JOURNAL, 2006, 27 (09) : 1010 - 1012
  • [43] New Perspectives for Antiplatelet Therapy: The Evolution of P2Y12 Receptor Antagonists
    da Silva, Paula Nogueira
    Barbosa, Maria Leticia de Castro
    REVISTA VIRTUAL DE QUIMICA, 2021, 13 (04) : 999 - 1016
  • [44] A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs
    Fayaz, S. M. A.
    Rajanikant, G. K.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (12) : 1625 - 1634
  • [45] Molecular mechanisms of platelet P2Y12 receptor regulation
    Cunningham, Margaret R.
    Nisar, Shaista P.
    Mundell, Stuart J.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2013, 41 : 225 - 230
  • [46] Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet Agents
    Caldwell, Allorie T.
    Watkins, E. Blake
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 87 - 99
  • [47] Platelet inhibition by P2Y12 antagonists is potentiated by adenosine signalling activators
    Shih, Chih-Chin
    Chan, Melissa, V
    Kirkby, Nicholas S.
    Vojnovic, Ivana
    Mitchell, Jane A.
    Armstrong, Paul C.
    Warner, Timothy D.
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (23) : 4758 - 4771
  • [48] Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists
    Price, Matthew J.
    Barker, Colin M.
    BIOMARKERS IN MEDICINE, 2011, 5 (01) : 43 - 51
  • [49] What is the best dose of aspirin in association with P2Y12 antagonists? reply
    Warner, Timothy D.
    HEART, 2011, 97 (03) : 264 - 264
  • [50] Inhibition of platelet aggregation by GLS-409, an antagonist of both P2Y1 and P2Y12, is distinct from inhibition by selective P2Y1 and P2Y12 antagonists
    Gremmel, T.
    Yanachkov, I. B.
    Wright, G.
    Michelson, A. D.
    Frelinger, A. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 516 - 516